Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Receiving the vaccine, in Sochi. Photo: Dmitry Feoktistov\TASS via Getty Images
Russia's Sputnik V vaccine demonstrated nearly 92% efficacy against symptomatic cases of COVID-19 and provided complete protection against severe cases, according to a peer-reviewed analysis of a large clinical trial published in the medical journal the Lancet. The vaccine also appears to be safe.
Why it matters: This is the strongest evidence to date that the Russian vaccine is one of several highly-effective options in the global mix. Russia is almost entirely dependent on Sputnik V to vaccinate its own population, and over a dozen other countries have purchased doses.
- That number is likely to continue to rise, though Russia has thus far struggled to ramp up its manufacturing capacity.
- Russia hopes to vaccinate 60% of its population by year's end, per WSJ.
Flashback: Vladimir Putin announced in August that the vaccine had been approved despite very limited data, and then in November the state-run Gamaleya Research Institute claimed it was 92% effective, without initially providing supporting data.
- Both announcements were met with a great deal of international skepticism. But those doubts will be at least partially assuaged by the findings released on Tuesday.
Go deeper: The global line for coronavirus vaccines stretches back to 2023